Clinical trials: Sunitinib
Metastatic Renal Cell Carcinoma (mRCC)
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Patients with metastatic renal cell carcinoma (mRCC) who failed first-line therapy with sunitinib or pazopanib was treated with everolimus. Efficacy and safety of everolimus was evaluated in these patients.
- Trial name
- NCT01514448
- Testing
- Everolimus (RAD001)
- Where
- 13 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Renal Cell
Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer
This is a randomised, double-blind, cross-over study of pazopanib versus sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC) who have received no prior systemic therapy for advanced or metastatic…
- Trial name
- PISCES (NCT01064310)
- Testing
- pazopanib, sunitinib
- Where
- 51 sites in Finland, France and 3 more
- Volunteers
- 169 people
- Sponsor
- Novartis Pharmaceuticals
Progressive Sarcoma
Treatment of Patients With RAD001 With Progressive Sarcoma
The purpose of this multicenter, three-arm, exact binomial single-stage, phase II trial is to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or…
- Trial name
- NCT00767819
- Testing
- Everolimus
- Where
- 6 sites in Germany, Italy
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy
This study will compare the safety and efficacy of sunitinib in combination with prednisone versus placebo and prednisone in patients that have metastatic castration-resistant prostate cancer that has progressed after treatment…
- Trial name
- SUN 1120 (NCT00676650)
- Testing
- Prednisone, sunitinib
- Where
- 205 sites in United States, Australia and 20 more
- Volunteers
- 873 people
- Sponsor
- Pfizer
Breast Neoplasms
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer
The treatment received with sunitinib plus capecitabine could delay tumor growth longer than with treatment with capecitabine alone.
- Trial name
- NCT00435409
- Testing
- Sunitinib + Capecitabine, Capecitabine
- Where
- 169 sites in United States, Austria and 16 more
- Volunteers
- 442 people
- Sponsor
- Pfizer
Kidney Cancer
Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00866320
- Testing
- sorafenib tosylate
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Case Comprehensive Cancer Center
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
This phase II trial studies how well giving sunitinib malate works in treating patients with iodine-refractory recurrent or metastatic thyroid cancer.
- Conditions
- Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer
- Trial name
- NCT00519896
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Glioblastoma Multiforme, Malignant Gliomas
Sunitinib to Treat Recurrent Brain Cancer
Background: One way tumors are able to grow is by forming new blood vessels that supply them with nutrients and oxygen. Sunitinib blocks certain proteins on the surface of tumor and blood vessel cells that are involved with the…
- Conditions
- Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas
- Trial name
- NCT00923117
- Testing
- Sutent (sunitinib)
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00891878
- Testing
- capecitabine, sunitinib malate
- Where
- 182 sites in United States
- Volunteers
- 12 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Anaplastic Astrocytoma, Glioblastoma
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
We are asked patients to take part in this study because they had recurrent (returned) (1st or 2nd) anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM).
- Trial name
- NCT00606008
- Testing
- Sunitinib Malate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Carcinoma, Renal Cell
Study of SU011248 in Patients With Advanced Kidney Cancer
To determine the objective tumor response of single-agent SU011248 at a dose of 50 mg orally once daily for 4 consecutive weeks and 2 weeks rest, repeated every 6 weeks in patients with metastatic Renal Cell Cancer (RCC).
- Trial name
- NCT00254540
- Testing
- SU011248 capsule
- Where
- 11 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Pfizer
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
This phase II trial studies how well giving sunitinib malate together with capecitabine works in treating patients with unresectable or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00787787
- Testing
- sunitinib malate, capecitabine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Washington
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00482911
- Testing
- cyclophosphamide, lenalidomide, sunitinib malate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Gastrointestinal Stromal Tumors
Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)
This is a phase II study of Nilotinib for patients with advanced GIST that cannot be surgically removed. Patients are candidates for the study if their tumors have progressed on imatinib and sunitinib or if they were intolerant…
- Trial name
- 07060 (NCT00782834)
- Testing
- Nilotinib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Fox Chase Cancer Center
Gastrointestinal Stromal Tumors
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
To monitor use in real practice including adverse events and efficacy on Sutent capsules (Sunitinib malate)
- Trial name
- NCT00444795
- Testing
- Sunitinib malate
- Where
- 47 sites in South Korea
- Volunteers
- 520 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
The goal of this clinical research study is to learn how CGT9486 (fka PLX9486) may affect cancer cells with certain mutations in the KIT gene, specifically in participants with types of advanced solid tumors including…
- Trial name
- NCT02401815
- Testing
- CGT9486, Pexidartinib, Sunitinib
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Cogent Biosciences, Inc.
Liver Neoplasms, Unresectable Hepatocellular Carcinoma
An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer
The study will consist of two parts. In Part 1 the study will start enrolling 38 patients and then further 25 patients up to a total of 63 eligible patients.
- Trial name
- NCT00247676
- Testing
- Sunitinib (SU011248)
- Where
- 8 sites in France, South Korea and 1 more
- Volunteers
- 37 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors
Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib
The study evaluated the safety and efficacy of nilotinib versus current treatment in adults with gastrointestinal stromal tumors (GIST) who have either progressed or who were intolerant to the first and second line treatments.
- Trial name
- ENEST (NCT00471328)
- Testing
- Nilotinib, Best Supportive Care (BSC) +/- imatinib or sunitinib
- Where
- 35 sites in United States, Australia and 11 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Advanced/Metastatic Breast Cancer
Study Of Sunitinib With Capecitabine In Breast Cancer
To evaluate efficacy, safety and pharmacokinetics of sunitinib plus Capecitabine in Japanese patients with advanced/metastatic breast cancer.
- Trial name
- NCT00662025
- Testing
- Capecitabine, Sunitinib
- Where
- 17 sites in Japan
- Volunteers
- 63 people
- Sponsor
- Pfizer